F XII |
| |
Authors: | G Fuhrer M J Gallimore W Heller H -E Hoffmeister |
| |
Institution: | (1) Kreiskrankenhaus Reutlingen, Steinenbergstrasse 31, W-7410 Reutlingen, Germany;(2) Department of Heart, Thoracic and Cardiovascular Surgery, University of Tübingen, W-7400 Tübingen, Germany |
| |
Abstract: | Summary The plasma protein F XII (Hageman factor) has been shown to be linked with the plasma defence systems of coagulation, fibrinolysis, kallikrein-kinin and complement. It can be activated by surface contact activation and in solution. Surface contact activation is a complex phenomenon involving negatively charged surfaces, F XII, high molecular weight kininogen and plasma kallikrein. Fluid-phase activation can be effected by a variety of serine proteases. In both types of activation the F XII zymogen is converted to active enzymes. F XII levels in plasma are low or undetectable in both inherited deficiencies and in a variety of clinical conditions. F XII levels can also be elevated in some clinical conditions. Although discovered as a clotting protein F XII appears to play an important role in the kallikrein-kinin and fibrinolytic systems and also has effects on cells. Recent studies suggest that therapeutic blockade of activation of F XII can be of benefit in certain clinical conditions. |
| |
Keywords: | F XII (Hageman factor) Activation Inhibition Prekallikrein High-molecular-weight kininogen F XII Coagulation Fibrinolysis Complement Clinical studies |
本文献已被 SpringerLink 等数据库收录! |
|